David Clemow is a Medical Affairs Principal Clinical Research Scientist at Eli Lilly and Company, specializing in medical affairs across drug development phases. They have a PhD in neuroscience and a background in clinical research, medical writing, and project management. David has contributed to billion-dollar global assets and has successfully led initiatives for the launch preparedness of lasmiditan, resulting in significant cost savings and improved communication. With a strong commitment to leadership and collaboration, David actively engages with professional associations and has over 30 published research and professional manuscripts.
This person is not in the org chart
This person is not in any teams
This person is not in any offices